The sources behind what we say
about life after the final period.

STRAW+10 is the international staging system that defines the final menstrual period (FMP) and treats 12 months of amenorrhoea as the marker of postmenopause.

Harlow et al · STRAW+10 collaborative

STRAW+10 is the staging document NAMS, IMS, ACOG and most national bodies refer back to. It also explicitly names the late-perimenopause stage where cycles get long and erratic before the FMP, useful when you're trying to work out where you are.

The Menopause Society (formerly NAMS) defines menopause as the day after 12 consecutive months without a menstrual period and treats everything after as postmenopause.

Patient-facing version of the same rule. Worth bookmarking if you ever need to point a doctor or HR person at a credible definition.

NICE (UK) uses the same 12-month definition and recommends diagnosis on symptoms alone for women over 45, blood tests rarely add useful information.

If you're being told you need an FSH test to 'confirm menopause' over 45, this is the page to send back. NICE explicitly says symptoms are enough.

Median total duration of frequent vasomotor symptoms in SWAN was 7.4 years, with a median 4.5 years post-FMP.

Avis et al · SWAN, n=1449

This is the paper most modern menopause writing quotes when it says '7 years'. Worth knowing the duration varies sharply by ethnicity. Black women in SWAN had the longest median, white women shorter, with East Asian shortest.

Roughly one in three women in SWAN had moderate-to-severe vasomotor symptoms continuing 10+ years past the final menstrual period.

Avis et al · SWAN long-term follow-up

If you've been quietly told 'you should be over this by now', this is the data that says: a third of women aren't, and that's known, not exceptional.

Fezolinetant, a non-hormonal NK3-receptor antagonist, reduces moderate-to-severe vasomotor symptom frequency and severity in postmenopausal women.

Johnson et al · phase 3, n=484

Useful evidence to bring to a postmenopausal-bleeding-history or breast-cancer-history conversation where systemic estrogen isn't on the table.

Up to 80% of postmenopausal women experience GSM symptoms, and most do not raise it with a clinician unless asked directly.

If your appointment doesn't include the question 'how are things vaginally / urinary-wise', it's a fair one to raise unprompted.

Low-dose vaginal estrogen is effective for GSM and the systemic absorption is minimal, including, with appropriate counselling, in women with a history of breast cancer.

This is the citation to bring if your oncology team has reflexively said 'no estrogen, ever'. The committee opinion explicitly carves out vaginal estrogen as a separate conversation.

Vaginal estrogen reduces recurrent urinary tract infection rates in postmenopausal women.

If you're getting recurrent UTIs in your 50s or 60s, this is one of the most-evidenced, and least-prescribed, interventions for it.

International Menopause Society practice recommendation: GSM is chronic and progressive, and treatment should be ongoing rather than time-limited.

Helpful for the 'can I just take it for six months and stop' conversation. The honest answer is: GSM tends to come back when you stop, because the tissue change does.

Postmenopausal ovaries continue producing low-level androgens and, intermittently, small amounts of estradiol for years after the FMP.

Fogle et al · ovarian steroidogenesis after menopause

The mechanistic basis for why cyclical-feeling symptoms are biologically plausible postmenopause, even when periods have stopped.

Pulsatile GnRH-driven LH/FSH activity persists after menopause and continues to oscillate, providing a possible substrate for cyclical symptom patterns.

Useful background reading on why the 'rhythm' of perimenopause doesn't fully switch off, the brain side of the system keeps oscillating long after the ovaries quiet down.

Women's menstrual cycles show weak but statistically detectable synchronisation with the lunar cycle, particularly in women in their early 30s and beyond, and synchrony declines with artificial light exposure.

Helfrich-Förster et al · 22-year self-tracked cycle dataset

Not menopause-specific, but the most-cited modern paper on lunar entrainment of female reproductive rhythms, relevant if your 'phantom' cycle reads moon-shaped rather than 28-day-shaped.

Any vaginal bleeding 12 or more months after the FMP is postmenopausal bleeding (PMB) and warrants prompt investigation (transvaginal ultrasound and/or endometrial biopsy) to rule out endometrial cancer.

Critical safety point that belongs next to anything about cyclical symptoms after menopause. Cyclical *cramps* without bleeding are usually benign. Actual *bleeding* a year or more after your last period is not, until proven otherwise.

Bone mineral density falls fastest in the year before and the 1–3 years after the final menstrual period.

Finkelstein et al · SWAN bone, n=1902

The data behind 'the perimenopause-to-early-postmenopause window matters most for bone'. bone-density (DEXA) is most informative if you do it within this window.

Starting menopausal hormone therapy in women under 60 or within 10 years of menopause does not increase coronary heart disease risk and may modestly reduce all-cause mortality.

The 'timing hypothesis' that drives most modern HRT recommendations. Useful when you want to read the actual numbers behind 'started early, lower risk' rather than the headline.

Women's cardiovascular risk rises sharply in the decade after menopause, and lipid changes (LDL up, HDL particle quality down) begin in late perimenopause.

If your last lipid panel was pre-menopause, it's reasonable to ask for a fresh one in the first couple of years post-FMP, the picture often shifts.